Lassen Therapeutics

Executive Summary

Lassen Therapeutics is a San Diego-based private biotech company founded in 2019, focused on developing novel antibody therapeutics targeting interleukin-11 (IL-11), a key cytokine driving fibrosis and inflammation. Its lead program, LASN-01, is a best-in-class neutralizing antibody against IL-11 that has advanced into Phase 2 clinical trials for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis. The company leverages proprietary antibody engineering platforms to build a pipeline of biologics with potential in multiple fibrotic and inflammatory indications. Lassen's approach targets a central pathway in fibrosis, which could offer a differentiated mechanism compared to approved therapies.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data for LASN-01 in IPF45% success
• Q2 2027Initiation of Phase 2 trial in systemic sclerosis60% success
• H2 2026Potential strategic partnership or licensing deal for pipeline30% success